Why is Astec Lifescienc falling/rising?

As of 16-Jul, Astec Lifesciences Ltd is currently priced at 929.00, reflecting an increase of 7.0 (0.76%). The stock has shown positive performance today, outperforming its sector by 1.33%. It is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bullish trend. However, despite a 2.35% increase over the past week and a 15.27% rise over the past month, the stock has experienced significant declines over the longer term, with a year-to-date drop of 7.56% and a staggering 30.39% decrease over the past year. The recent increase in promoter confidence, with a 4.12% increase in their stake, suggests a belief in the company's future potential, but this is countered by weak long-term fundamentals, including negative operating cash flow and a high debt-to-EBITDA ratio.
Broader market context indicates that while Astec Lifesciences has outperformed the Sensex in the short term, the stock has consistently underperformed against broader benchmarks over the last three years. The Sensex has gained 5.75% year-to-date, contrasting sharply with Astec's negative returns. This divergence highlights the stock's ongoing struggles despite recent positive movements, as it continues to face challenges such as declining sales and profitability, which may deter long-term investors.